双侧大结节性肾上腺病的长期随访与遗传管理
该回顾性研究在巴西三级中心随访了17个家族性及9例散发性双侧大结节性肾上腺病(BMAD)患者,共纳入250人。结果显示104人携带ARMC5致病/可能致病变异,ARMC5阳性索引病例皮质醇升高且ACTH与DHEAS降低;保留肾上腺手术缓解率100%,单侧肾上腺切除为40%。作者提出管理流程图强调基因筛查与持续监测。
要点
- 家族性BMAD应进行ARMC5基因筛查,阳性者需长期监测皮质醇与肿瘤风险。
- ARMC5阳性索引病例皮质醇水平更高、ACTH与DHEAS更低、肾上腺结节更大。
- 保留肾上腺手术缓解率100%,优于单侧肾上腺切除的40%。
核心结论
- BMAD长期管理需结合基因筛查与持续监测,以降低肾上腺功能不全、MACS复发及肿瘤风险。
- 治疗策略应根据遗传改变及ARMC5状态个体化制定。
研究设计与样本
- 回顾性研究,随访17个家族性及9例散发性BMAD病例,随访时间8至410个月,于巴西三级中心开展。
- 共纳入250人(50例索引病例和200名亲属),评估临床、激素、影像、组织学及ARMC5与KDM1A基因分析。
主要发现
- 250人中104人(26例索引病例和78名亲属)携带胚系ARMC5致病/可能致病变异。
- ARMC5野生型患者中未发现KDM1A(可能)致病变异。
- ARMC5阳性索引病例皮质醇水平升高(尿、唾液及地塞米松抑制试验后),ACTH和DHEAS降低(P=.005、P=.042、P=.005、P=.041和P=.007)。
- 索引病例肾上腺结节更大(P<.0001)。
- 保留肾上腺手术缓解率100%,单侧肾上腺切除缓解率40%;中枢神经系统脑膜瘤与ARMC5状态无关;恶性肿瘤在ARMC5改变个体中显著常见。
关键数值与推荐
- ARMC5阳性索引病例尿皮质醇、唾液皮质醇及地塞米松抑制试验后皮质醇升高,ACTH和DHEAS降低,对应P值分别为.005、.042、.005、.041和.007。
- 索引病例肾上腺结节更大,P<.0001。
- 保留肾上腺手术缓解率100%,单侧肾上腺切除缓解率40%。
临床怎么用
- 对家族性BMAD患者应开展ARMC5基因筛查,阳性者需长期监测皮质醇水平及肿瘤发生。
- 手术方式选择需权衡缓解率与肾上腺功能保护,保留肾上腺手术可能提高缓解率。
- 随访中需警惕肾上腺功能不全、MACS复发及合并肿瘤风险。
局限性
- 回顾性研究设计。
- 样本量有限(17个家族性及9例散发性BMAD病例)。
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Bilateral macronodular adrenocortical disease (BMAD) is a rare and often underdiagnosed cause of adrenal Cushing syndrome (CS), with manifestations ranging from mild autonomous cortisol secretion (MACS) to overt CS. ARMC5 and KDM1A are the most frequently implicated genes in familial BMAD; however, long-term follow-up data on affected patients remain limited. OBJECTIVE: This retrospective study assessed the clinical and hormonal variability, genetic profiles, treatment approaches, and outcomes of 17 familial and 9 sporadic BMAD cases over a follow-up period ranging from 8 to 410 months at a Brazilian tertiary center. METHODS: A total of 250 individuals (50 index cases and 200 relatives) were included. Clinical, hormonal, and imaging data, along with histological and genetic analyses of ARMC5 and KDM1A, were evaluated. RESULTS: Among 250 individuals, 104 (26 index and 78 relatives) carried germline pathogenic/likely pathogenic ARMC5 variants. No KDM1A (likely) pathogenic variants were identified in ARMC5-wild-type patients. ARMC5-positive index cases exhibited severe clinical manifestations, evidenced by elevated cortisol levels (urinary, salivary, and post-dexamethasone suppression test) and reduced ACTH and DHEAS levels (P = .005, P = .042, P = .005, P = .041, and P = .007, respectively). Index cases had larger adrenal nodules (P < .0001). Adrenal-sparing surgery achieved 100% remission vs a 40% remission rate for unilateral adrenalectomy. Central nervous system meningiomas were observed in BMAD patients independent of ARMC5 status. Interestingly, malignant neoplasms were notably prevalent among ARMC5-altered individuals. CONCLUSION: The proposed management flowchart highlights the importance of genetic screening and continuous monitoring to mitigate the adrenal insufficiency, MACS recurrence, and tumor risk, while underscoring the need for tailored therapeutic strategies in BMAD, adapted to genetic alterations and ARMC5 status.
引用
- Charchar HLS, Alencar GA, de Paula Mariani BM, et al. A Global Approach to the Long-Term Follow-Up of 17 Families With Bilateral Macronodular Adrenal Disease. J Clin Endocrinol Metab. 2026. PMID: 40810200. doi:10.1210/clinem/dgaf465
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。